{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.85","upperLimit":"35.56","value":"1.38"},{"groupId":"OG001","lowerLimit":"1.44","upperLimit":"12.25","value":"7.88"},{"groupId":"OG002","lowerLimit":"0.85","upperLimit":"14.88","value":"1.15"},{"groupId":"OG003","lowerLimit":"0.68","upperLimit":"88.27","value":"5.025"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"6"}],"units":"Participants"}],"description":"PFS is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first. Progression was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) and is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study).","dispersionType":"Full Range","groups":[{"description":"Phase I Dose Level (DL) 1 Topotecan 1mg/m\\^2 intravenous (IV) (days 1-5); VX970 (M6620) 140mg/m\\^2 IV on day 5","id":"OG000","title":"Phase I DL1 Topotecan 1mg/m^2 Intravenous (IV) (Days 1-5); VX970 (M6620) 140mg/m^2 IV on Day 5"},{"description":"Phase I Dose Level (DL) 2 Topotecan 1mg/m\\^2 intravenous (IV) (days 1-5); VX970 (M6620) 140mg/m\\^2 IV on day 2, 5","id":"OG001","title":"Phase I DL2 Topotecan 1mg/m^2 Intravenous (IV) (Days 1-5); VX970 (M6620) 140mg/m^2 IV on Day 2, 5"},{"description":"Phase I Dose Level (DL) 3 Topotecan 1.25mg/m\\^2 intravenous (IV) (days 1-5); VX970 (M6620) 140mg/m\\^2 IV on day 2, 5","id":"OG002","title":"Phase I DL3 Topotecan 1.25mg/m^2 Intravenous(IV) (Days 1-5); VX970 (M6620) 140mg/m^2 IV on Day 2, 5"},{"description":"Phase I Dose Level (DL) 4 Topotecan 1.25mg/m\\^2 intravenous (IV) (days 1-5); VX970 (M6620) 210mg/m\\^2 IV on day 2, 5","id":"OG003","title":"Phase I DL4 Topotecan 1.25mg/m^2 Intravenous(IV) (Days 1-5); VX970 (M6620) 210mg/m^2 IV on Day 2, 5"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"At disease progression - 0.68 months to 88.27 months, an Average Mean of 10.6 months","title":"Phase I: Progression-free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"Months"}